drugset / Trial / NCT00150202

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

NCT00150202

Phase 3 Completed 90 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.

Timeline

Start
2004-07
Primary completion
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer

Indications